SCHEMBL3159101

SCHEMBL3159101

O=C(NC1Cc2ccccc2C1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 5/20 0.61
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
ALDH1A1 P00352 6/20 0.55
CA1 P00915 2/20 0.55
RXFP1 Q9HBX9 1/20 0.53
LMNA P02545 3/20 0.53
POLB P06746 2/20 0.53
USP2 O75604 1/20 0.53
HTT P42858 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP3A4 P08684 1/20 0.53
PTGS1 P23219 1/20 0.53
KDM4E B2RXH2 1/20 0.51
CYP2C9 P11712 1/20 0.51
EDNRA P25101 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2287872 0.86 MEN1 (0.61) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL12377117 0.84 SCN3A (0.59) SCN3AMEN1KMT2ACA1SCN5A
SCHEMBL3154101 0.83 SCN3A (0.56) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL12377114 0.82 MEN1 (0.50) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL2625954 0.81 SCN3A (0.57) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL12377124 0.80 MEN1 (0.57) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL3169820 0.80 SCN3A (0.63) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL3165638 0.78 SCN3A (0.58) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL3159830 0.78 SCN3A (0.58) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL12377113 0.77 CA1 (0.49) SCN3AMEN1KMT2AALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885MEN1 4729/4885KMT2A 1920/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885MEN1 4729/4885KMT2A 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.